Mark Lanier, representing widow Carol Ernst, displayed the phrase "Merck-y ethics" on a large screen and promised to skewer the judgment of a company he said knew the popular painkiller could be dangerous years before a study showed it could double risk of heart attack or stroke. That study prompted Merck to voluntarily remove it from the market last year.
In a much more subdued presentation, Merck lawyer David Kiernan, who is also a surgeon, urged jurors to keep an open mind as Merck seeks to show the company didn't rush a lucrative drug to market and slip shoddy science past the U.S. Food and Drug Administration to pump up profits.
"That charge could not be more false," he said.
Ernst's husband, Robert, a personal trainer, died in his sleep four years ago of an arrhythmia, or irregular heartbeat. He had been taking Vioxx for about eight months to ease pain in his hands.
Lawyers from throughout the country associated with other Vioxx lawsuits packed the courtroom for hours of opening statements — more than two hours afforded each side.
The trial resumes Monday afternoon with the beginning of testimony.
Kiernan said Vioxx has been in development since 1991 and cut in half the potentially lethal stomach bleeding that some patients got from traditional pain relievers like aspirin.
Vioxx was tested in 58 clinical trials involving 10,000 patients before it went on the market, he said, far surpassing FDA testing recommendations.
Buttressed by photos, graphics and documents shown on a large screen behind him, Lanier targeted former Merck CEO Ray Gilmartin. He described Gilmartin as the first non-doctor or non-scientist — "a Harvard-trained businessman" — to run Merck, starting in 1994.
Lanier said Gilmartin aimed to turn Merck into "an ATM machine that's spitting out money" by beefing up sales with glitzy television ads for various drugs — including Vioxx, which came on the market in 1999.
Vioxx was critical to Merck, Lanier alleged, because patents on other lucrative drugs ran out in 2000 and 2001 and "if Vioxx doesn't fill up the ATM machine for us, we're running dry. It's Vioxx or bust."
He said the company downplayed studies that raised concerns about Vioxx's safety and pushed the painkiller to a growing market of arthritis sufferers and their doctors to keep the bottom line robust.
"You watch what happens to their studies. It will make you sick," Lanier said.